Physician profile
Deep Phachu
NPI 1912435736
$1,903.49
in general payments reported to CMS, 2019-2025
19 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $620 · 2023: $543 · 2024: $559 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.72 |
| Education | $108.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $303.17 | 2022-2024 | Jynarque |
| Glaxosmithkline, LLC. | $268.20 | 2022-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $205.89 | 2023-2025 | Terlivaz |
| Amgen INC. | $171.73 | 2022-2025 | Tavneos |
| Akebia Therapeutics INC | $124.26 | 2022-2024 | Auryxia |
| Astrazeneca Pharmaceuticals LP | $118.19 | 2022-2025 | Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $111.45 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $104.73 | 2022-2024 | Tarpeyo |
| Vifor Pharma, INC. | $104.54 | 2022-2023 | Veltassa |
| Travere Therapeutics, INC. | $88.79 | 2024-2025 | Filspari |
| Baxter Healthcare | $70.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $53.99 | 2024-2025 | |
| Scpharmaceuticals INC. | $51.33 | 2024-2025 | |
| Lilly USA, LLC | $32.81 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.02 | 2024 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $20.49 | 2023 | Ultomiris |
| Aurinia Pharma U.S., INC. | $19.69 | 2024 | Lupkynis |
| Genzyme Corporation | $16.75 | 2024 | |
| Horizon Therapeutics Plc | $12.88 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Phachu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.